Syn-Coll vs Vesugen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Syn-Coll is a palmitoylated tripeptide (Palmitoyl Tripeptide-5) that mimics thrombospondin-1 to activate TGF-beta, the primary growth factor driving collagen synthesis in the dermis. It is one of the most mechanistically direct collagen-stimulating peptides in cosmetic formulations.
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- Half-Life
- Extended (lipid depot in stratum corneum)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.005-0.05% in formulation
- 10 mg per day
- Frequency
- Once or twice daily
- Daily for 10–30 days
- Key Benefits
- Directly activates TGF-beta for potent collagen synthesis stimulation
- Increases dermal thickness and firmness
- Reduces depth of wrinkles and fine lines
- Improves skin elasticity
- Clinically validated in collagen induction studies
- Complementary to retinoids or vitamin C
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Side Effects
- Generally well-tolerated
- Rare mild irritation at high concentrations
- Possible sensitivity in individuals with inflammatory skin conditions
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Stacks With
- —
- —